HighMark Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

HighMark Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.2K	Hold	221	–	–	0.01%	203
2025 Q4	$27K	Buy	221 +1	+0.5%	+$115	0.01%	219
2025 Q3	$22.1K	Hold	220	–	–	0.01%	227
2025 Q2	$18.3K	Hold	220	–	–	0.01%	234
2025 Q1	$17.9K	Sell	220 -1,404	-86%	-$125K	0.01%	206
2024 Q4	$146K	Sell	1,624 -599	-27%	-$58K	0.08%	69
2024 Q3	$220K	Hold	2,223	–	–	0.12%	61
2024 Q2	$206K	Buy	2,223 +3	+0.1%	+$269	0.12%	61
2024 Q1	$211K	Hold	2,220	–	–	0.13%	58
2023 Q4	$198K	Sell	2,220 -25	-1%	-$1.86K	0.15%	55
2023 Q3	$164K	Hold	2,245	–	–	0.14%	50
2023 Q2	$187K	Hold	2,245	–	–	0.14%	51
2023 Q1	$171K	Hold	2,245	–	–	0.13%	61
2022 Q4	$186K	Hold	2,245	–	–	0.14%	50
2022 Q3	$178K	Hold	2,245	–	–	0.15%	51
2022 Q2	$167K	Sell	2,245 -575	-20%	-$43.2K	0.13%	50
2022 Q1	$253K	Hold	2,820	–	–	0.17%	44
2021 Q4	$316K	Buy	2,820 +2,575	+1,051%	+$311K	0.2%	41
2021 Q3	$31K	Buy	+245	New	+$31.6K	0.02%	146

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

HighMark Wealth Management's XBI Position: Q1 2026 in Review

HighMark Wealth Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 221 shares worth $28.2K. The position accounts for 0.01% of the portfolio, ranked #203.

HighMark Wealth Management first reported a position in XBI in Q3 2021 and has held it in 19 quarters since. The position peaked at $316K in Q4 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

HighMark Wealth Management held 221 shares of State Street SPDR S&P Biotech ETF worth $28.2K as of Q1 2026.
HighMark Wealth Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of HighMark Wealth Management's portfolio in Q1 2026, its #203 holding.
HighMark Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and has held it in 19 quarters since.
HighMark Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $316K in Q4 2021.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on HighMark Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.